Hepato Papers “Disease Etiology and Outcomes After Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma: Post-Hoc Analysis of IMbrave150”

---

Disease Etiology and Outcomes After Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma: Post-Hoc Analysis of IMbrave150 é o novo artigo comentado do Hepato Papers, comentado pelo hepatologista, Dr. Fábio Marinho.